BioAge Labs Under Investigation for Securities Violations
The Schall Law Firm, a national firm dedicated to protecting shareholder rights, is currently investigating allegations against BioAge Labs, Inc. (“BioAge” or “the Company”) BIOA. This inquiry centers on possible violations of securities laws.
Company Faces Scrutiny After Major Trial Suspension
The investigation seeks to determine if BioAge misled investors by failing to disclose critical information regarding its operations. Recently, on December 9, 2024, the Company halted its STRIDES Phase 2 trial for azelaprag due to safety concerns about elevated liver transaminase levels observed in participants. Prior to this announcement, BioAge had touted azelaprag’s potential benefits for those receiving obesity treatment with incretin drugs. As a direct consequence of this news, BioAge’s stock plummeted over 76.8% on the same day.
Investors who have experienced losses are urged to participate in this inquiry. For more information and to discuss your rights, please contact Brian Schall of the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or call 310-301-3335. You can also reach the firm through its website at www.schallfirm.com or via email at bschall@schallfirm.com.
The Schall Law Firm represents investors worldwide and focuses on securities class action lawsuits and shareholder rights issues.
This press release may be interpreted as Attorney Advertising in certain jurisdictions according to applicable laws and ethical standards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209124151/en/
Market News and Data brought to you by Benzinga APIs
